If this hypothesis is correct, new therapeutic approaches should aim at overcoming the disruption of the nuclear lamina and nucleoporins at the earliest possible or presymptomatic stage, thereby preventing or delaying the neurodegeneration associated with FUS-ALS. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.